476 related articles for article (PubMed ID: 22942289)
1. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner.
Eckford PD; Li C; Ramjeesingh M; Bear CE
J Biol Chem; 2012 Oct; 287(44):36639-49. PubMed ID: 22942289
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.
Lin WY; Sohma Y; Hwang TC
Mol Pharmacol; 2016 Sep; 90(3):275-85. PubMed ID: 27413118
[TBL] [Abstract][Full Text] [Related]
3. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
[TBL] [Abstract][Full Text] [Related]
4. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.
Jih KY; Hwang TC
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4404-9. PubMed ID: 23440202
[TBL] [Abstract][Full Text] [Related]
5. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
Yu YC; Sohma Y; Hwang TC
J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
[TBL] [Abstract][Full Text] [Related]
6. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
Yeh JT; Yu YC; Hwang TC
J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
[TBL] [Abstract][Full Text] [Related]
7. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
[TBL] [Abstract][Full Text] [Related]
8. Physiological and pharmacological characterization of the N1303K mutant CFTR.
DeStefano S; Gees M; Hwang TC
J Cyst Fibros; 2018 Sep; 17(5):573-581. PubMed ID: 29887518
[TBL] [Abstract][Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability.
Liu X; Dawson DC
Biochemistry; 2014 Sep; 53(35):5613-8. PubMed ID: 25148434
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of the cystic fibrosis transmembrane conductance regulator Cl
Wang Y; Cai Z; Gosling M; Sheppard DN
Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L846-L857. PubMed ID: 30136610
[TBL] [Abstract][Full Text] [Related]
11. A common mechanism for CFTR potentiators.
Yeh HI; Sohma Y; Conrath K; Hwang TC
J Gen Physiol; 2017 Dec; 149(12):1105-1118. PubMed ID: 29079713
[TBL] [Abstract][Full Text] [Related]
12. Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770).
Delaunay JL; Bruneau A; Hoffmann B; Durand-Schneider AM; Barbu V; Jacquemin E; Maurice M; Housset C; Callebaut I; Aït-Slimane T
Hepatology; 2017 Feb; 65(2):560-570. PubMed ID: 28012258
[TBL] [Abstract][Full Text] [Related]
13. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains.
Wang W; Bernard K; Li G; Kirk KL
J Biol Chem; 2007 Feb; 282(7):4533-4544. PubMed ID: 17178710
[TBL] [Abstract][Full Text] [Related]
14. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
[TBL] [Abstract][Full Text] [Related]
15. Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor.
Li H; Rodrat M; Al-Salmani MK; Veselu DF; Han ST; Raraigh KS; Cutting GR; Sheppard DN
J Physiol; 2024 Jan; 602(2):333-354. PubMed ID: 38186087
[TBL] [Abstract][Full Text] [Related]
16. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants.
Veit G; Da Fonte DF; Avramescu RG; Premchandar A; Bagdany M; Xu H; Bensinger D; Stubba D; Schmidt B; Matouk E; Lukacs GL
J Cyst Fibros; 2020 Mar; 19(2):236-244. PubMed ID: 31678009
[TBL] [Abstract][Full Text] [Related]
17. Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity.
Prins S; Langron E; Hastings C; Hill EJ; Stefan AC; Griffin LD; Vergani P
J Biol Chem; 2020 Dec; 295(49):16529-16544. PubMed ID: 32934006
[TBL] [Abstract][Full Text] [Related]
18. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.
Van Goor F; Yu H; Burton B; Hoffman BJ
J Cyst Fibros; 2014 Jan; 13(1):29-36. PubMed ID: 23891399
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations.
Csanády L; Töröcsik B
Elife; 2019 Jun; 8():. PubMed ID: 31205003
[TBL] [Abstract][Full Text] [Related]
20. The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.
Raju SV; Lin VY; Liu L; McNicholas CM; Karki S; Sloane PA; Tang L; Jackson PL; Wang W; Wilson L; Macon KJ; Mazur M; Kappes JC; DeLucas LJ; Barnes S; Kirk K; Tearney GJ; Rowe SM
Am J Respir Cell Mol Biol; 2017 Jan; 56(1):99-108. PubMed ID: 27585394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]